Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $45.4286.

Several brokerages have recently weighed in on SION. Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Raymond James Financial reissued a “strong-buy” rating and set a $53.00 price target on shares of Sionna Therapeutics in a report on Monday, January 5th. BTIG Research raised their price objective on Sionna Therapeutics from $50.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, Lifesci Capital assumed coverage on Sionna Therapeutics in a research note on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 price objective for the company.

Sionna Therapeutics Stock Down 7.4%

NASDAQ SION opened at $36.34 on Tuesday. The company has a 50-day moving average price of $40.44 and a 200-day moving average price of $30.28. Sionna Therapeutics has a 52 week low of $7.26 and a 52 week high of $45.00. The firm has a market capitalization of $1.62 billion and a P/E ratio of -7.46.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. sold 311,000 shares of the company’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $39.50, for a total value of $12,284,500.00. Following the completion of the transaction, the director owned 219,867 shares of the company’s stock, valued at approximately $8,684,746.50. This represents a 58.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Peter A. Thompson sold 94,583 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $44.54, for a total value of $4,212,726.82. Following the completion of the sale, the director owned 3,610,376 shares of the company’s stock, valued at $160,806,147.04. The trade was a 2.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 1,442,988 shares of company stock valued at $54,475,865. Insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

A number of hedge funds have recently made changes to their positions in SION. Russell Investments Group Ltd. purchased a new stake in shares of Sionna Therapeutics during the third quarter worth about $30,000. BNP Paribas Financial Markets purchased a new stake in Sionna Therapeutics during the 2nd quarter valued at approximately $31,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Sionna Therapeutics during the second quarter valued at approximately $45,000. Virtus Investment Advisers LLC purchased a new position in shares of Sionna Therapeutics in the second quarter worth $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Sionna Therapeutics during the second quarter worth $117,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.